| Sponsored by | |
 |
|
Track 1
Friday, March 9, 2012
Session 1
The Innovators Dilemma – How do we Reinvent the Life Sciences R&D Model
9:45AM – 11:00AM
Ten key trends are driving significant changes in the R&D model in Life Sciences and pharmaceutical and biotech companies will need to adapt. This presentation articulate the vision of the way that R&D will need to change in the future world and the nine components that will drive success based on external research that was conducted with several leading pharmaceutical and biotech clients. This vision for the future R&D operating model is relevant to both large pharmaceutical companies, trying to drive out costs while significantly improving product innovation and also biotech companies, seeking to scale up faster and more economically while also linking into the broader innovation ecosystem.
Moderator
Roland Andersson, Ph.D.
Senior Executive, Accenture
Panel Speakers
Terry Hermiston, Ph.D.
Vice President of Biologics Research & USIC Site Head
Bayer Healthcare
Session 2
Now for Something Completely Different: How will Pharma Access External Early-Stage Innovation?
11:30AM – 12:45PM
The number of NMEs (new molecular entities) approved each year by the FDA is insufficient to maintain a robust pharmaceutical industry; the number of big pharma and large biotechs is shrinking via mergers and attrition and the pressure to rapidly advance late stage projects through the pipeline is intense. Pharma has responded to these conditions by shifting resources to later stage projects at the expense of funding higher risk, early-stage programs. In this environment, how and by whom will early-stage innovation be funded? And, without early-stage innovation, what will happen to the drug pipeline in the next 5 to 15 years? In order to address these issues, pharma is turning more toward the external world and making a significant investment (time, resources and money) in academic and early stage biotechs. But, how is this best done? Past industry-academic relationships have not been generally successful, so how will future pharma forays into the academic and biotech space be conducted? This panel will discuss how their respective organizations are leveraging external sources to their advantage. The panelists represent four of the largest pharmaceutical companies- Merck, Pfizer, Sanofi and Johnson & Johnson and they will discuss how they are differentiating themselves from their competitors; the merits of their approaches; and perhaps look into the future to predict what pharma will look like in 2017 and 2022.
Moderator
Mervyn Turner, Ph.D.
Advisor, Bay City Capital
Panel Speakers
Remi Brouard, M.D.
Vice President External Innovation, Sanofi
Christopher Haskell, Ph.D.
Head, US Science Hub
Bayer Healthcare
Ron Newbold, Ph.D.
Vice President, Pfizer
Melinda Richter, MBA
Executive Director/CEO, Janssen Labs/Prescience International
Jim Schaeffer, Ph.D.
Executive Director, Merck Research Labs
Session 3
Leading Edge Tools, Technologies and Approaches for Drug Discovery
2:30PM – 3:45PM
To survive as an industry we have to do a better job at discovering, validating and demonstrating the benefit of novel drugs. Traditional therapeutic hunting methods are improving and new genomics based and other innovative strategies are emerging with the potential to revolutionize the process of drug discovery. This session will focus on the current state of affairs of drug discovery, what we have learned as an industry about what works and what doesn’t, and how new technologies will impact drug discovery productivity. Companies realize patients are individuals, and not populations; the decoding of the human genome in conjunction with the newest advances in next-generation sequencing technology is opening the door to therapeutic target identification and patient specific treatment strategies we never had access to before. A plethora of novel drug discovery platform technology, chemistry and biologics companies are forging ahead into new space. In this session luminary speakers from the pharmaceutical, biotech, investment and academic sectors, who are pushing the boundaries of current science and technology to find the right drug for the right patient at the right dose and right time, will discuss the future of drug discovery.
Moderator
Brian Atwood
Managing Director, Versant Ventures
Panel Speakers
Ned David, Ph.D.
Venture Partner, ARCH Ventures
John Mendlein
CEO and Executive Chairman, aTyr Pharma
H. Martin Seidel
Director, The Genomics Institute of the Novartis Research Foundation (GNF)
Mike Varney
Senior Vice President: Small Molecule Drug Discovery, Genentech, Inc.
